Comparison of patient, transplantation, and GVHD variables across tolerant and non-tolerant groups.

*categorical data compared with Fisher’s exact test or Chi-square, continuous data utilized wilcoxon rank sum test* AA—aplastic anemia; ALL—acute lymphoblastic leukemia; AML—acute myelogenous leukemia; CML—chronic myelogenous leukemia; FL—follicular lymphoma; HD—Hodgkin lymphoma; IMF—idiopathic myelofibrosis; MCL—mantle cell lymphoma; MDS—myelodysplastic syndrome; MM—multiple myeloma; MPD—myeloproliferative neoplasm; PBSC—peripheral blood stem cells; BM—bone marrow harvested stem cells; MMUD—mismatched unrelated donor; MRD—matched sibling donor; MUD—matched unrelated donor; HLA—human leukocyte antigen; CMV—cytomegalovirus; neg—negative; pos—positive; Bu—busulfan; Cy—cyclophosphamide; Flu—fludarabine; ATG—anti-thymocyte globulin; R—rituximab; BCNU—carmustine; VP16—etoposide; TBI—total body irradiation; pento—pentostatin; CSA—cyclosporine; TAC—tacrolimus; MMF—mycophenolate mofetil; MTX—methotrexate; aGVHD—acute graft vs. host disease; pred—prednisone; rapa—rapamycin (sirolimus); ECP—extra-corporeal photopheresis; cGVHD—chronic graft vs. host diseaseComparison of patient, transplantation, and GVHD variables across tolerant and non-tolerant groups.